The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-VEGF Injection Market Research Report 2025
Synopsis
The global Anti-VEGF Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Anti-VEGF Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Anti-VEGF Injection include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Injection.
Report Scope
The Anti-VEGF Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Segment by Type
Ranibizumab
Bevacizumab
Aflibercept
Brolucizumab
Others
Segment by Application
Age-related Macular Degeneration (AMD)
Diabetic Retinopathy
Retinal Vein Occlusion (RVO)
Retinopathy of Prematurity (ROP)
Uveitis
Neovascular Glaucoma
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Anti-VEGF Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Anti-VEGF Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-VEGF Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Anti-VEGF Injection include Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., Regeneron, Qilu Pharmaceutical Co.,Ltd., Innovent Biologics and Anke Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-VEGF Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF Injection.
Report Scope
The Anti-VEGF Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-VEGF Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-VEGF Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Bayer
Genentech
Novartis
Coherus BioSciences Inc.
Regeneron
Qilu Pharmaceutical Co.,Ltd.
Innovent Biologics
Anke Biotechnology
Shenzhen Kangzhe Pharmaceutical Co Ltd
Chengdu Kanghong Pharmaceutical Group
Segment by Type
Ranibizumab
Bevacizumab
Aflibercept
Brolucizumab
Others
Segment by Application
Age-related Macular Degeneration (AMD)
Diabetic Retinopathy
Retinal Vein Occlusion (RVO)
Retinopathy of Prematurity (ROP)
Uveitis
Neovascular Glaucoma
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-VEGF Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-VEGF Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-VEGF Injection Market Overview
1.1 Product Overview and Scope of Anti-VEGF Injection
1.2 Anti-VEGF Injection Segment by Type
1.2.1 Global Anti-VEGF Injection Market Value Comparison by Type (2024-2030)
1.2.2 Ranibizumab
1.2.3 Bevacizumab
1.2.4 Aflibercept
1.2.5 Brolucizumab
1.2.6 Others
1.3 Anti-VEGF Injection Segment by Application
1.3.1 Global Anti-VEGF Injection Market Value by Application: (2024-2030)
1.3.2 Age-related Macular Degeneration (AMD)
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion (RVO)
1.3.5 Retinopathy of Prematurity (ROP)
1.3.6 Uveitis
1.3.7 Neovascular Glaucoma
1.3.8 Others
1.4 Global Anti-VEGF Injection Market Size Estimates and Forecasts
1.4.1 Global Anti-VEGF Injection Revenue 2019-2030
1.4.2 Global Anti-VEGF Injection Sales 2019-2030
1.4.3 Global Anti-VEGF Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-VEGF Injection Market Competition by Manufacturers
2.1 Global Anti-VEGF Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-VEGF Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-VEGF Injection Average Price by Manufacturers (2019-2024)
2.4 Global Anti-VEGF Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-VEGF Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-VEGF Injection, Product Type & Application
2.7 Anti-VEGF Injection Market Competitive Situation and Trends
2.7.1 Anti-VEGF Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-VEGF Injection Players Market Share by Revenue
2.7.3 Global Anti-VEGF Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-VEGF Injection Retrospective Market Scenario by Region
3.1 Global Anti-VEGF Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-VEGF Injection Global Anti-VEGF Injection Sales by Region: 2019-2030
3.2.1 Global Anti-VEGF Injection Sales by Region: 2019-2024
3.2.2 Global Anti-VEGF Injection Sales by Region: 2025-2030
3.3 Global Anti-VEGF Injection Global Anti-VEGF Injection Revenue by Region: 2019-2030
3.3.1 Global Anti-VEGF Injection Revenue by Region: 2019-2024
3.3.2 Global Anti-VEGF Injection Revenue by Region: 2025-2030
3.4 North America Anti-VEGF Injection Market Facts & Figures by Country
3.4.1 North America Anti-VEGF Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-VEGF Injection Sales by Country (2019-2030)
3.4.3 North America Anti-VEGF Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Anti-VEGF Injection Market Facts & Figures by Country
3.5.1 Europe Anti-VEGF Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-VEGF Injection Sales by Country (2019-2030)
3.5.3 Europe Anti-VEGF Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Anti-VEGF Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-VEGF Injection Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-VEGF Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-VEGF Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Anti-VEGF Injection Market Facts & Figures by Country
3.7.1 Latin America Anti-VEGF Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-VEGF Injection Sales by Country (2019-2030)
3.7.3 Latin America Anti-VEGF Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-VEGF Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-VEGF Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-VEGF Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-VEGF Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-VEGF Injection Sales by Type (2019-2030)
4.1.1 Global Anti-VEGF Injection Sales by Type (2019-2024)
4.1.2 Global Anti-VEGF Injection Sales by Type (2025-2030)
4.1.3 Global Anti-VEGF Injection Sales Market Share by Type (2019-2030)
4.2 Global Anti-VEGF Injection Revenue by Type (2019-2030)
4.2.1 Global Anti-VEGF Injection Revenue by Type (2019-2024)
4.2.2 Global Anti-VEGF Injection Revenue by Type (2025-2030)
4.2.3 Global Anti-VEGF Injection Revenue Market Share by Type (2019-2030)
4.3 Global Anti-VEGF Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-VEGF Injection Sales by Application (2019-2030)
5.1.1 Global Anti-VEGF Injection Sales by Application (2019-2024)
5.1.2 Global Anti-VEGF Injection Sales by Application (2025-2030)
5.1.3 Global Anti-VEGF Injection Sales Market Share by Application (2019-2030)
5.2 Global Anti-VEGF Injection Revenue by Application (2019-2030)
5.2.1 Global Anti-VEGF Injection Revenue by Application (2019-2024)
5.2.2 Global Anti-VEGF Injection Revenue by Application (2025-2030)
5.2.3 Global Anti-VEGF Injection Revenue Market Share by Application (2019-2030)
5.3 Global Anti-VEGF Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Anti-VEGF Injection Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Anti-VEGF Injection Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Genentech
6.3.1 Genentech Corporation Information
6.3.2 Genentech Description and Business Overview
6.3.3 Genentech Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Genentech Anti-VEGF Injection Product Portfolio
6.3.5 Genentech Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Anti-VEGF Injection Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Coherus BioSciences Inc.
6.5.1 Coherus BioSciences Inc. Corporation Information
6.5.2 Coherus BioSciences Inc. Description and Business Overview
6.5.3 Coherus BioSciences Inc. Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Coherus BioSciences Inc. Anti-VEGF Injection Product Portfolio
6.5.5 Coherus BioSciences Inc. Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Regeneron Anti-VEGF Injection Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Qilu Pharmaceutical Co.,Ltd.
6.6.1 Qilu Pharmaceutical Co.,Ltd. Corporation Information
6.6.2 Qilu Pharmaceutical Co.,Ltd. Description and Business Overview
6.6.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product Portfolio
6.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
6.8 Innovent Biologics
6.8.1 Innovent Biologics Corporation Information
6.8.2 Innovent Biologics Description and Business Overview
6.8.3 Innovent Biologics Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Innovent Biologics Anti-VEGF Injection Product Portfolio
6.8.5 Innovent Biologics Recent Developments/Updates
6.9 Anke Biotechnology
6.9.1 Anke Biotechnology Corporation Information
6.9.2 Anke Biotechnology Description and Business Overview
6.9.3 Anke Biotechnology Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anke Biotechnology Anti-VEGF Injection Product Portfolio
6.9.5 Anke Biotechnology Recent Developments/Updates
6.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
6.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Corporation Information
6.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Description and Business Overview
6.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product Portfolio
6.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
6.11 Chengdu Kanghong Pharmaceutical Group
6.11.1 Chengdu Kanghong Pharmaceutical Group Corporation Information
6.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Description and Business Overview
6.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product Portfolio
6.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-VEGF Injection Industry Chain Analysis
7.2 Anti-VEGF Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-VEGF Injection Production Mode & Process
7.4 Anti-VEGF Injection Sales and Marketing
7.4.1 Anti-VEGF Injection Sales Channels
7.4.2 Anti-VEGF Injection Distributors
7.5 Anti-VEGF Injection Customers
8 Anti-VEGF Injection Market Dynamics
8.1 Anti-VEGF Injection Industry Trends
8.2 Anti-VEGF Injection Market Drivers
8.3 Anti-VEGF Injection Market Challenges
8.4 Anti-VEGF Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-VEGF Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Anti-VEGF Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Anti-VEGF Injection Market Competitive Situation by Manufacturers in 2023
Table 4. Global Anti-VEGF Injection Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Anti-VEGF Injection Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Anti-VEGF Injection Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Anti-VEGF Injection Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Anti-VEGF Injection Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Anti-VEGF Injection, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGF Injection, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGF Injection, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGF Injection, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGF Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Injection as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anti-VEGF Injection Sales by Region (2019-2024) & (K Units)
Table 18. Global Anti-VEGF Injection Sales Market Share by Region (2019-2024)
Table 19. Global Anti-VEGF Injection Sales by Region (2025-2030) & (K Units)
Table 20. Global Anti-VEGF Injection Sales Market Share by Region (2025-2030)
Table 21. Global Anti-VEGF Injection Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Anti-VEGF Injection Revenue Market Share by Region (2019-2024)
Table 23. Global Anti-VEGF Injection Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Anti-VEGF Injection Revenue Market Share by Region (2025-2030)
Table 25. North America Anti-VEGF Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 27. North America Anti-VEGF Injection Sales by Country (2025-2030) & (K Units)
Table 28. North America Anti-VEGF Injection Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Anti-VEGF Injection Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Anti-VEGF Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 32. Europe Anti-VEGF Injection Sales by Country (2025-2030) & (K Units)
Table 33. Europe Anti-VEGF Injection Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Anti-VEGF Injection Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Anti-VEGF Injection Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Anti-VEGF Injection Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Anti-VEGF Injection Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Anti-VEGF Injection Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Anti-VEGF Injection Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-VEGF Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Anti-VEGF Injection Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Anti-VEGF Injection Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-VEGF Injection Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-VEGF Injection Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Anti-VEGF Injection Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Anti-VEGF Injection Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Anti-VEGF Injection Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-VEGF Injection Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Anti-VEGF Injection Sales (K Units) by Type (2019-2024)
Table 51. Global Anti-VEGF Injection Sales (K Units) by Type (2025-2030)
Table 52. Global Anti-VEGF Injection Sales Market Share by Type (2019-2024)
Table 53. Global Anti-VEGF Injection Sales Market Share by Type (2025-2030)
Table 54. Global Anti-VEGF Injection Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Anti-VEGF Injection Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Anti-VEGF Injection Revenue Market Share by Type (2019-2024)
Table 57. Global Anti-VEGF Injection Revenue Market Share by Type (2025-2030)
Table 58. Global Anti-VEGF Injection Price (US$/Unit) by Type (2019-2024)
Table 59. Global Anti-VEGF Injection Price (US$/Unit) by Type (2025-2030)
Table 60. Global Anti-VEGF Injection Sales (K Units) by Application (2019-2024)
Table 61. Global Anti-VEGF Injection Sales (K Units) by Application (2025-2030)
Table 62. Global Anti-VEGF Injection Sales Market Share by Application (2019-2024)
Table 63. Global Anti-VEGF Injection Sales Market Share by Application (2025-2030)
Table 64. Global Anti-VEGF Injection Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Anti-VEGF Injection Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Anti-VEGF Injection Revenue Market Share by Application (2019-2024)
Table 67. Global Anti-VEGF Injection Revenue Market Share by Application (2025-2030)
Table 68. Global Anti-VEGF Injection Price (US$/Unit) by Application (2019-2024)
Table 69. Global Anti-VEGF Injection Price (US$/Unit) by Application (2025-2030)
Table 70. Roche Corporation Information
Table 71. Roche Description and Business Overview
Table 72. Roche Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Roche Anti-VEGF Injection Product
Table 74. Roche Recent Developments/Updates
Table 75. Bayer Corporation Information
Table 76. Bayer Description and Business Overview
Table 77. Bayer Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Bayer Anti-VEGF Injection Product
Table 79. Bayer Recent Developments/Updates
Table 80. Genentech Corporation Information
Table 81. Genentech Description and Business Overview
Table 82. Genentech Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Genentech Anti-VEGF Injection Product
Table 84. Genentech Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Anti-VEGF Injection Product
Table 89. Novartis Recent Developments/Updates
Table 90. Coherus BioSciences Inc. Corporation Information
Table 91. Coherus BioSciences Inc. Description and Business Overview
Table 92. Coherus BioSciences Inc. Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Coherus BioSciences Inc. Anti-VEGF Injection Product
Table 94. Coherus BioSciences Inc. Recent Developments/Updates
Table 95. Regeneron Corporation Information
Table 96. Regeneron Description and Business Overview
Table 97. Regeneron Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Regeneron Anti-VEGF Injection Product
Table 99. Regeneron Recent Developments/Updates
Table 100. Qilu Pharmaceutical Co.,Ltd. Corporation Information
Table 101. Qilu Pharmaceutical Co.,Ltd. Description and Business Overview
Table 102. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Injection Product
Table 104. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 105. Innovent Biologics Corporation Information
Table 106. Innovent Biologics Description and Business Overview
Table 107. Innovent Biologics Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Innovent Biologics Anti-VEGF Injection Product
Table 109. Innovent Biologics Recent Developments/Updates
Table 110. Anke Biotechnology Corporation Information
Table 111. Anke Biotechnology Description and Business Overview
Table 112. Anke Biotechnology Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Anke Biotechnology Anti-VEGF Injection Product
Table 114. Anke Biotechnology Recent Developments/Updates
Table 115. Shenzhen Kangzhe Pharmaceutical Co Ltd Corporation Information
Table 116. Shenzhen Kangzhe Pharmaceutical Co Ltd Description and Business Overview
Table 117. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Injection Product
Table 119. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 120. Chengdu Kanghong Pharmaceutical Group Corporation Information
Table 121. Chengdu Kanghong Pharmaceutical Group Description and Business Overview
Table 122. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Injection Product
Table 124. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Anti-VEGF Injection Distributors List
Table 128. Anti-VEGF Injection Customers List
Table 129. Anti-VEGF Injection Market Trends
Table 130. Anti-VEGF Injection Market Drivers
Table 131. Anti-VEGF Injection Market Challenges
Table 132. Anti-VEGF Injection Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-VEGF Injection
Figure 2. Global Anti-VEGF Injection Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-VEGF Injection Market Share by Type in 2023 & 2030
Figure 4. Ranibizumab Product Picture
Figure 5. Bevacizumab Product Picture
Figure 6. Aflibercept Product Picture
Figure 7. Brolucizumab Product Picture
Figure 8. Others Product Picture
Figure 9. Global Anti-VEGF Injection Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Anti-VEGF Injection Market Share by Application in 2023 & 2030
Figure 11. Age-related Macular Degeneration (AMD)
Figure 12. Diabetic Retinopathy
Figure 13. Retinal Vein Occlusion (RVO)
Figure 14. Retinopathy of Prematurity (ROP)
Figure 15. Uveitis
Figure 16. Neovascular Glaucoma
Figure 17. Others
Figure 18. Global Anti-VEGF Injection Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Anti-VEGF Injection Market Size (2019-2030) & (US$ Million)
Figure 20. Global Anti-VEGF Injection Sales (2019-2030) & (K Units)
Figure 21. Global Anti-VEGF Injection Average Price (US$/Unit) & (2019-2030)
Figure 22. Anti-VEGF Injection Report Years Considered
Figure 23. Anti-VEGF Injection Sales Share by Manufacturers in 2023
Figure 24. Global Anti-VEGF Injection Revenue Share by Manufacturers in 2023
Figure 25. The Global 5 and 10 Largest Anti-VEGF Injection Players: Market Share by Revenue in 2023
Figure 26. Anti-VEGF Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 27. Global Anti-VEGF Injection Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 28. North America Anti-VEGF Injection Sales Market Share by Country (2019-2030)
Figure 29. North America Anti-VEGF Injection Revenue Market Share by Country (2019-2030)
Figure 30. United States Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Canada Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Europe Anti-VEGF Injection Sales Market Share by Country (2019-2030)
Figure 33. Europe Anti-VEGF Injection Revenue Market Share by Country (2019-2030)
Figure 34. Germany Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. France Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. U.K. Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Italy Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Netherlands Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Asia Pacific Anti-VEGF Injection Sales Market Share by Region (2019-2030)
Figure 40. Asia Pacific Anti-VEGF Injection Revenue Market Share by Region (2019-2030)
Figure 41. China Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Australia Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Anti-VEGF Injection Sales Market Share by Country (2019-2030)
Figure 49. Latin America Anti-VEGF Injection Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Anti-VEGF Injection Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Anti-VEGF Injection Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Anti-VEGF Injection Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Anti-VEGF Injection by Type (2019-2030)
Figure 59. Global Revenue Market Share of Anti-VEGF Injection by Type (2019-2030)
Figure 60. Global Anti-VEGF Injection Price (US$/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Anti-VEGF Injection by Application (2019-2030)
Figure 62. Global Revenue Market Share of Anti-VEGF Injection by Application (2019-2030)
Figure 63. Global Anti-VEGF Injection Price (US$/Unit) by Application (2019-2030)
Figure 64. Anti-VEGF Injection Value Chain
Figure 65. Anti-VEGF Injection Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
